teriparatide
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoporosis, Post-Menopausal
Conditions
Osteoporosis, Post-Menopausal
Trial Timeline
Nov 1, 2003 → Dec 1, 2004
NCT ID
NCT00532207About teriparatide
teriparatide is a phase 3 stage product being developed by Eli Lilly for Osteoporosis, Post-Menopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00532207. Target conditions include Osteoporosis, Post-Menopausal.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01705587 | Approved | Completed |
| NCT01360424 | Approved | Completed |
| NCT00826228 | Approved | Completed |
| NCT00696644 | Pre-clinical | Completed |
| NCT00535860 | Phase 2 | Completed |
| NCT00577863 | Phase 3 | Completed |
| NCT00557310 | Approved | Completed |
| NCT00259298 | Approved | Completed |
| NCT00191867 | Phase 2 | Completed |
| NCT00191321 | Phase 3 | Completed |
| NCT00532207 | Phase 3 | Completed |
| NCT00191893 | Phase 3 | Completed |
| NCT00191802 | Phase 3 | Completed |
| NCT00532545 | Approved | Completed |
Competing Products
20 competing products in Osteoporosis, Post-Menopausal